Has Julio Peguero, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,002,402 in general payments to Julio Peguero, MD across 1,929 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Julio Peguero, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Julio Peguero, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Julio Peguero, MD

Internal Medicine · Houston, TXNPI 1659569507

Payments from drug & device makers

$7,002,402in general payments, 2019–2025

Across 1,929 payments — averaging $3630.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$1.9M
Mirati Therapeutics, Inc.$819K
Janssen Research & Development, LLC$654K
EMD Serono, Inc.$413K
Eli Lilly$370K
Amgen$313K
plus $2.6M from 54 others

$11,298in research payments, 2019–2025

Across 5 payments — averaging $2259.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$8K
AbbVie$2K
Regeneron$768

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	67	$1,872,992
Mirati Therapeutics, Inc.	34	$819,304
Janssen Research & Development, LLC	70	$654,005
EMD Serono, Inc.	165	$413,074
Eli Lilly	32	$369,840
Amgen	61	$313,284
Novartis	128	$312,807
Aadi Bioscience, Inc.	5	$298,201
Ipsen Bioscience Inc.	18	$220,200
AVEO Pharmaceuticals, Inc.	24	$189,659
Beigene, Ltd.	28	$182,616
GSK	82	$168,447
AstraZeneca(2 entities)	21	$139,452
Kyowa Kirin, Inc.	73	$114,975
Tersera Therapeutics LLC	11	$113,338
Regeneron	33	$85,017
Incyte Corporation	111	$83,414
AbbVie	32	$78,664
Trillium Therapeutics USA, LLC	14	$78,156
Pfizer	99	$73,018
Takeda Pharmaceuticals U.S.A., Inc.	17	$70,786
Bayer	31	$56,159
Seagen Inc.	22	$48,031
Astrazeneca UK Limited	2	$38,171
Genentech, Inc.	2	$36,915
E.r. Squibb & Sons, L.L.C.	140	$30,305
Novocure Inc.	10	$25,679
Veloxis Pharmaceuticals, Inc.	2	$22,750
Epizyme, Inc.	3	$20,155
Gilead(2 entities)	28	$18,923
Ares Trading SA	35	$18,206
Daiichi Sankyo Inc.	14	$14,609
Macrogenics, Inc.	6	$5,526
Exelixis Inc.	10	$4,010
Johnson & Johnson(2 entities)	97	$1,762
Bristol Myers Squibb	51	$1,085
Sanofi	33	$756
Bard Peripheral Vascular, Inc.	1	$716
Pharmacyclics LLC, An Abbvie Company	25	$610
Telix Pharmaceuticals	6	$570
Eisai Inc.	24	$470
Beigene USA, Inc.	23	$413
Tempus AI, Inc	26	$392
Astellas Pharma US Inc	19	$389
Genentech USA, Inc.	19	$383
Taiho Oncology, Inc.	16	$353
F. Hoffmann-la Roche AG	2	$348
Springworks Therapeutics, Inc.	17	$266
Pharmaessentia USA Corporation	11	$230
Jazz Pharmaceuticals Inc.	8	$219
Myriad Genetic Laboratories, Inc.	2	$186
Deciphera Pharmaceuticals Inc.	7	$177
Puma Biotechnology, Inc.	8	$173
Lilly USA, LLC	10	$162
Ipsen Biopharmaceuticals, Inc	3	$160
Sanofi-aventis U.S. LLC	4	$154
Regeneron Healthcare Solutions, Inc.	6	$117
Sirtex Medical Inc	5	$112
Teva Pharmaceuticals USA, Inc.	5	$105
Array Biopharma Inc	4	$102

How this compares

$7,002,402 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas →

Medicare billing

Part B allowed, 2024

$766,754

Medicare patients

177

Services billed

36,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Houston

Jan BurgerHouston$47.3M
Nitin JainHouston$33.2M
Aung NaingHouston$30.6M
Preetesh JainHouston$19.5M
Paolo StratiHouston$19.2M
Nicholas ShortHouston$17.6M
Isabella GlitzaHouston$14.8M
Murtaza MussajiHouston$13.1M
Hussein TawbiHouston$12.6M
Hans LeeHouston$11.7M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →